1De Marzo AM,Platz EA,Sutcliffe S,Xu J,Gronberg H,Drake CG,Nakai Y,Isaacs WB,and Nelson WG).Inflammation in prostate carcinogenesis[J].Nat Rev Cancer,2007,7:256.
2Wang D and DuBois RN.Inflammatory mediators and nuclear receptorsignaling in colorectal cancer[J].Cell Cycle,2007,6:682.
3Diaz-Cruz ES and Brueggemeier RW (2006).Interrelationships between cyclooxygenases and aromatase:unraveling the relevance of cyclooxygenase inhibitors in breast cancer[J].Anticancer Agents Med Chem,2006,6:221.
4Chang SH,Liu CH,Conway R,Han DK,Nithipatikom K,Trifan OC,Lane TF,and Hla T.Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression[J].Proc Natl Acad Sci USA,2004,101:591.
5Stasinopoulos I,O'Brien DR,Wildes F,Glunde K,and Bhujwalla ZM.Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells[J].Mol Cancer Res,2007,5:435.
6Gupta GP,Nguyen DX,Chiang AC,Bos PD,Kim JY,Nadal C,Gomis RR,Manova-Todorova K,and Massague J.Mediators of vascular remodeling co-opted for sequential steps in lung metastasis[J].Nature,2007,446:765.
7Kutchera W,Jones DA,Matsunami N,et al.Prostaglandin H synthase 2 is expressed abnormally in human colon cancer:evidence for a transcriptional effect[J].Proc Natl Acad Sci USA,1996,93(10):4816.
8Smith WL,DeWitt DL and Garavito RM.Cyclooxygenases:Structure,cellular and molecular biology[J].Annu Rev Biochem,2000,69(1):145.
9Half E,Tang XM,Gwyn K,et al.Cyclooxygenase-2expression inhuman breast cancers and adiacent ductal carcinoma in situ[J].Cancer Res,2002,62(6):1676.
10Spizzo C,Gastl C,et al.Correlation of COX-2 and Ep-CAM overexpression in human invasive al[J].Br J Cancer,2003,88(4):574.
1Mita AC, Mita MM, Nawrocki ST, et al. Survivin : key regulator of mitosis and apoptosis and novel target for cancer therapeutics[ J]. Clin Cancer Res,2008,14 ( 16 ) :5000- 5005.
2Rexhepaj E, Jirstrom K, OConnor DP, et al. Validation of cytoplas- mic-to-nuclear ratio of snrvivin as an indicator of improved progno- sis in breast cancer[J]. BMC Cancer,2010,23(10) :639.
3Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression pre- dicts early recurrence in early-stage breast cancer[ J ]. Anti Cancer Res, 2007,27 ( 4 ) : 2803- 2808.
4Hafftye G,Yang Q, Moran MS, et al. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation [ J]. Int J Radia Oncol Biol Phys,2008,71 (4) :1006-1013.
5Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase- 2 in- hibitor, celecoxib,prevents the development of mammarytumors in Her- 2/neu mice Cancer [ J ]. Epidemiol Biomarkers JP, 2003,12 ( 12 ) : 1486-1491.
6Yonemaru K, Sakai H, Murakami M, et al. Expression of vascular endotyelial growth factor, basic fibroblast growth factor, and their receptors ( fit- 1,ilk- 1, and fig- 1 ) in canine vascular tumors [ J ]. Vet Pathol,2006,43 (6) :971-980.
7Faridi A, Rudlowskic, Schun S, et al. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor expression in patients with breast cancer [ J ]. Pathol Res Pract, 2002,198 ( 1 ) : 1-5.
8Krysan K, Dalwadi H, Sharama S, et al. Cyclooxygenase-2-depend- ent expression of survivin is critical for apoptosis resistance in non- small cell lung cancer [ J ]. Cancer Res, 2004,64 ( 18 ) : 6359- 6362.
9Mehar A, Macanas-Pirard P,Mizokami A,et al. The effects of cy- clooxygenase-2 expression in prostate cancercells: modulation of reaponse to cytotoxic agents[ J]. J Pharmacol Exp Ther,2008,324 (3) :1181-1187.
10Majima M, Hayashi I, Muramatsu M, et al. Cyclooxygenase-2 en- chances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge im- plants[ J]. Bri J Pharm ,2000,130 ( 3 ) :641-649.
